AI’s role in the next era of longevity biotech
Insilico Medicine CEO Alex Zhavoronkov describes integrated AI platforms (Biology 42, Chemistry 42, Medicine for You) that compress drug discovery timelines and prioritize aging-related targets while highlighting regulatory and safety constraints.
Why it mattersInsilico's Biology 42 compressing discovery to 14 months forces investors to accelerate early-stage due diligence.